Full Text
HTA138 NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs

Abstract

Authors

R Dey

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×